证券代码：688581 证券简称：安杰思 公告编号：2024-033 杭州安杰思医学科技股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 杭州安杰思医学科技股份有限公司（以下简称"公司"）第二届监事会第十一次 会议于 2024 年 08 月 07 日以现场结合通讯的方式在公司二楼大会议室召开。本次会议 通知已于 2024 年 07 月 26 日以专人送达方式向全体监事发出，本次会议由监事会主席 时百明主持，会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集和召开程序 符合《公司法》和《公司章程》的有关规定。 会议由监事会主席时百明主持召开，全体与会监事经认真审议和表决，形成以下 决议： 二、监事会会议审议情况 （一）审议通过了《关于 2024 年半年度募集资金存放与实际使用情况的专项报告 的议案》 监事会认为：公司监事会根据《上海证券交易所科创板股票上市规则》《募集资 金管理制度》等相关规定，编制了《2024 年半年度募集资金存放与实际使用情况的专 ...

杭州安杰思医学科技股份有限公司 2023 年限制性股票激励计划 授予价格、数量调整及预留授予相关事项的 法律意见 电话:0571-86508080 传真:0571-87357755 邮编:31001 浙江省杭州市上城区新业路 200 号华峰国际大厦 10 楼 | 一、 | 本激励计划授予价格、数量调整及预留授予的批准和授权 5 | | --- | --- | | 二、 | 本激励计划授予价格、数量调整的相关内容 7 | | 三、 | 本次预留授予的授予日 8 | | 四、 | 本次预留授予的授予条件 9 | | 五、 | 本次预留授予的对象、价格和数量 10 | | 六、 | 结论意见 10 | 北京德恒（杭州）律师事务所 关于 北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2023 年限制性股票激励计划 授予价格、数量调整及预留授予相关事项的法律意见 北京德恒（杭州）律师事务所 关于 杭州安杰思医学科技股份有限公司 2023 年限制性股票激励计划 授予价格、数量调整及预留授予相关事项的 法律意见 德恒 12F20230465-3 号 致：杭州安杰思医学科技股份有限公司 北京德恒（杭州）律师 ...

杭州安杰思医学科技股份有限公司 关于调整 2023 年限制性股票激励计划 相关事项的公告 证券代码：688581 证券简称：安杰思 公告编号：2024-036 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安杰思医学科技股份有限公司（以下简称"本公司"或"公司"）2024 年8月7日召开第二届董事会第十五次会议、第二届监事会第十一次会议，审议通 过了《关于调整2023年限制性股票激励计划相关事项的议案》，同意董事会根据 《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《杭州安杰思 医学科技股份有限公司2023年限制性股票激励计划（草案）》（以下简称"《激 励计划》"或"本激励计划"）的相关规定及公司2023年第二次临时股东大会的 授权，对公司2023年限制性股票激励计划（以下简称"本次激励计划"）的相关 事项进行调整，现将有关事项说明如下： 一、本次激励计划已履行的决策程序和信息披露情况 1、2023 年 8 月 14 日，公司召开第二届董事会第六次会议，审议通过了《关于 公司<2023 年限制性股票激励计 ...

杭州安杰思医学科技股份有限公司（以下简称"公司"）于 2024 年 8 月 7 日 召开了第二届董事会第十五次会议，审议通过了《关于公司变更注册资本及修订 <公司章程>的议案》与《关于制定公司部分治理制度的议案》其中《关于公司变 更注册资本及修订<公司章程>的议案》尚需提交公司 2024 年第二次临时股东大 会审议。具体情况如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司注册资本变更情况 公司于 2024 年 5 月 14 日召开 2023 年年度股东大会，会议审议通过了《关 于 2023 年度利润分配预案的议案》，以 2023 年度权益分派股权登记日的总股 本（扣减回购专用证券账户的股份）为基数进行利润分配，向全体股东每 10 股 派发现金红利 14.5 元（含税），且每 10 股派送红股 4 股（含税）。公司回购专 用证券账户持股数为 401,398 股，公司总股本（扣减回购专用证券账户的股份） 为 57,469,573 股，以此计算合计派发现金红利 83,330,880.85 元（含税），合 计派送红 ...

杭州安杰思医学科技股份有限公司 监事会关于公司2023年限制性股票激励计划 预留授予激励对象名单的核查意见 杭州安杰思医学科技股份有限公司（以下简称"公司"）监事会依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简 称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）、《科创板上市公司自律监管指南第4 号——股权激励信 息披露》等法律、法规及规范性文件和《杭州安杰思医学科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，对公司2023年限制性股票激励计 划（以下简称"本激励计划"）预留授予激励对象名单（截至预留授予日）进 行审核，发表核查意见如下： 1、本激励计划预留授予的激励对象均不存在《管理办法》第八条规定的不 得成为激励对象的下列情形： （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 2、本激励计划预留授予的激励对象为公司公告本激励计划时在公司（含 分、子公司，下同）任职的董事、高级管理人员、中层管理人员及核心技术 （业务）骨干。 ...

Financial Performance - The company achieved a revenue of RMB 1.23 billion in the first half of 2024, representing a year-on-year growth of 15.6%[1] - The gross profit margin for the period was 65.8%, an increase of 2.3 percentage points compared to the same period last year[1] - The company's net profit reached RMB 320 million, up by 18.4% year-on-year[1] - Revenue increased by 28.43% year-on-year to RMB 264 million, driven by strong growth in the Chinese and US markets, particularly in GI and ESD/EMR product categories[14] - Net profit attributable to shareholders rose by 57.93% to RMB 124.45 million, supported by increased sales, improved gross margins, and higher interest income[14] - Operating cash flow surged by 65.64% to RMB 116.27 million, reflecting higher cash inflows from sales[14] - Basic earnings per share (EPS) grew by 25.57% to RMB 1.5428, reflecting improved profitability[17] - Weighted average return on equity (ROE) decreased by 5.81 percentage points to 5.51%, primarily due to changes in equity structure[17] - Total revenue for the first half of 2024 reached 264,000,678.80 RMB, a 28.4% increase compared to 205,558,880.81 RMB in the same period of 2023[129] - Net profit attributable to the parent company increased to 437,635,027.29 RMB in the first half of 2024, up 6.1% from 412,335,342.45 RMB in the same period of 2023[128] - Net profit reached 124,453,227.74, a 58% increase year-over-year[130] - Operating profit grew to 145,089,365.64, up 61.7% compared to the same period last year[130] - Revenue from the parent company rose to 263,515,540.68, up 28.3% compared to the previous year[132] - Comprehensive income for the first half of 2024 reached 131,618,394.69 RMB, an increase from 79,266,307.59 RMB in the same period last year[135] R&D and Innovation - The R&D investment in the first half of 2024 was RMB 150 million, accounting for 12.2% of the total revenue[1] - R&D investment as a percentage of revenue increased by 1.03 percentage points to 9.79%, indicating a stronger focus on innovation[17] - The company's core technologies include bipolar circuit technology, clip-assisted tissue traction technology, reloadable technology, and continuous firing technology, with 11, 1, 11, and 1 patents granted respectively, and additional patents pending[28] - The company has developed fiber optic imaging (multimodal imaging technology) capable of high-resolution imaging on a 1mm diameter cross-section, with 6 patents pending[30] - The company is developing an endoscopic surgical assist robot, which is set to enter animal testing, with 7 patents pending[31] - The company has made progress in flexible endoscopes, solving operational issues and mastering core algorithms for light source selection and image processing, with 14 patents pending[32] - In the reporting period, the company applied for 39 new invention patents, 6 new utility model patents, and 5 new design patents, with a cumulative total of 54 invention patents, 39 utility model patents, and 4 design rights granted[33] - Total R&D investment increased by 43.60% to 25,851,895.22 yuan, with R&D investment accounting for 9.79% of total revenue, an increase of 1.03 percentage points[39] - R&D investment increased significantly due to higher spending on soft endoscopes and auxiliary therapeutic robots, as well as an increase in R&D personnel[40] - The number of R&D personnel increased to 127, accounting for 18.9% of the total workforce, up from 98 and 17.22% in the previous year[44] - R&D personnel's average salary increased to 11.43 from 10.81 in the previous year[44] Market Expansion and Sales - The company's overseas revenue grew by 25.3% year-on-year, reaching RMB 480 million[1] - The company completed the acquisition of a European medical device manufacturer for EUR 50 million, expanding its market presence in Europe[1] - The company's sales model includes distribution and ODM, with domestic sales primarily through distribution and overseas sales through ODM and distribution, expanding its own brand sales overseas[27] - The company successfully registered 32 new products in international markets, including Saudi Arabia, Thailand, and Paraguay[35][36] - The company expanded its product portfolio in Malaysia and Turkey by adding new specifications and series to existing products[38] - Asia-Pacific region sales revenue grew by 82.86%, North America by 68.49%, and South America by 53.74% year-over-year[50][51] - Overseas sales revenue increased by 35.28% year-on-year, with Asia-Pacific region growing by 82.86%, North America by 68.49%, and South America by 53.74%. Own-brand sales accounted for nearly 30%[55] - The Dutch subsidiary will commence physical operations in the second half of the year to expand the international marketing network[55] - The company added 14 new cooperative clients and participated in academic conferences such as DDW and ESGE DAYS[55] - The company expanded its hospital network by adding 198 new hospitals and 400 effective channels, with products covering 31 provinces, autonomous regions, and municipalities[54] - The company participated in over 60 academic conferences, including the 21st Wuhan Union Digestive Disease Conference and the 21st Beijing International Digestive Disease Forum, enhancing market penetration[54] Production and Operations - The company's new production facility in Hangzhou is expected to be operational by the end of 2024, with an annual production capacity of 50,000 units[1] - The company's production model includes domestic inventory and overseas order-based production, ensuring efficient production through collaboration between marketing, production, and quality departments[25] - Production output increased by over 30% year-over-year due to the application of lean production concepts and the use of new factory facilities[49] - The company's procurement model emphasizes quality, cost, and timely delivery, with a focus on establishing a supply chain and supplier management system that meets operational needs[26] - The company has achieved automated assembly for multiple processes of products like electrosurgical snares, biopsy forceps, and clip devices[57] - The company has obtained ISO 13485:2016 certification and market access qualifications in multiple countries including the US, EU, Japan, Canada, Brazil, Australia, UK, Switzerland, and South Korea[55] Financial Position and Cash Flow - The company's cash and cash equivalents stood at RMB 1.8 billion as of June 30, 2024, providing strong financial flexibility for future investments[1] - Operating cash flow surged by 65.64% to RMB 116.27 million, reflecting higher cash inflows from sales[14] - The company's cash and cash equivalents decreased from 1,954,739,150.26 as of December 31, 2023, to 964,766,200.12 as of June 30, 2024[123] - Net cash flow from operating activities for the first half of 2024 was 116,273,846.99 RMB, compared to 70,197,212.78 RMB in the same period last year[136] - Net cash flow from investing activities for the first half of 2024 was -992,813,720.80 RMB, a significant decrease from 31,145,027.33 RMB in 2023[136] - Net cash flow from financing activities for the first half of 2024 was -114,361,075.58 RMB, compared to 1,647,493,638.86 RMB in the same period last year[136] - The company's cash and cash equivalents at the end of the first half of 2024 were 964,759,200.12 RMB, down from 1,960,785,293.76 RMB at the end of 2023[137] - Cash received from other investment activities in the first half of 2024 was 449,985,159.85 RMB, a significant increase from 56,601,493.74 RMB in 2023[136] - Cash paid for other investment activities in the first half of 2024 was 1,417,427,542.27 RMB, compared to no significant amount in 2023[136] - Cash received from financing activities in the first half of 2024 was 1,820,326,000.00 RMB, compared to no significant amount in 2023[136] - The net increase in cash and cash equivalents for the first half of 2024 was -989,972,950.14 RMB, a significant decrease from 1,748,925,812.72 RMB in 2023[137] Market and Industry Trends - The global medical device market size reached $440 billion in 2020 and is expected to exceed $800 billion by 2030, with a CAGR of 6.3% from 2020 to 2030[23] - China's medical device market size grew from RMB 312.6 billion in 2015 to RMB 778.9 billion in 2020, with a CAGR of 20%, and is expected to exceed RMB 2.2 trillion by 2030, with a CAGR of 11% from 2020 to 2030[23] - The domestic gastrointestinal endoscopy diagnostic and therapeutic device market size is expected to grow from RMB 3.73 billion in 2019 to RMB 11.42 billion by 2030[24] - The global endoscopy diagnostic and therapeutic device market size is expected to grow from $5 billion in 2021 to $6 billion by 2024, with a CAGR of 6%[24] - Imported brands accounted for 93.1% of China's medical endoscope market in 2021, but domestic brands are expected to increase their market share to 18.3% by 2025 and 35.2% by 2030[24] - The company operates in the medical device manufacturing industry (C358) under the specialized equipment manufacturing sector (C35)[21] - The Chinese government has implemented policies to support innovation in medical devices, including optimizing approval processes, strengthening intellectual property protection, and promoting domestic equipment innovation[21] - The volume-based procurement policy for medical devices has promoted market competition, reduced procurement costs, and improved supply chain efficiency[21] - The DRG/DIP payment reform has encouraged medical institutions to actively control costs and standardize medical practices[21] - The company focuses on the research, production, and sales of minimally invasive endoscopic diagnostic and therapeutic devices, with a growing emphasis on technological innovation and domestic market expansion[21] - The domestic production rate of minimally invasive surgical consumables is expected to further increase, with domestic manufacturers gradually breaking through in mid-to-high-end products and potentially gaining more global market share[25] Intellectual Property and Patents - The company obtained 334 intellectual property rights, including 17 design patents and 7 software copyrights[34] - The company submitted 334 patent applications, with 97 authorized patents, including 54 invention patents, and 55% of patents applied in related products[53] - The company launched innovative products such as the reloadable hemostatic clip, which reduces clinical costs, and the coated guidewire for ERCP, which improves cannulation success rates[53] Risks and Challenges - The company faces intensified competition in both domestic and international markets for minimally invasive endoscopic devices[59] - The company has established a comprehensive quality system to prevent product performance defects and enhance brand influence[59] - The company's products, including biliary drainage tubes and high-frequency cutting knives, have been included in centralized procurement programs in multiple provinces, potentially impacting sales prices and profit margins[61] - The company faces risks from international trade friction and exchange rate fluctuations, as its primary export markets are in the EU and North America, with transactions primarily settled in USD[60] - Medical device industry policy changes, particularly the centralized procurement reform, may impact the company's operations and profitability[60] - The company is actively monitoring macroeconomic conditions and adjusting its business strategies to mitigate potential risks[61] - Intellectual property risks exist, particularly regarding the "AGS" trademark in the domestic market, which could affect product promotion and sales[61] - The company is implementing measures to retain technical talent and maintain its competitive advantage in innovation[63] Corporate Governance and Shareholder Commitments - The actual controller Zhang Cheng and related parties have committed to a 36-month lock-up period for their shares post-IPO, with specific conditions for extending the lock-up period if the stock price falls below the issue price for 20 consecutive trading days within 6 months of listing[85] - Zhang Cheng's immediate family members, Zhang Qianyi and Zhang Beijia, have also committed to a 36-month lock-up period for their indirectly held shares, with similar conditions for extending the lock-up period[86] - Major shareholders including Hangzhou Yijia, Ningbo Jiayi, and Ningbo Dingjie have committed to a 36-month lock-up period for their shares, with conditions for extending the lock-up period if the stock price falls below the issue price for 20 consecutive trading days within 6 months of listing[87] - The company has established a long-term effective dividend policy, as indicated in the 2024 semi-annual report[83] - The company has resolved issues related to competition with entities controlled by the actual controller, Zhang Cheng, and related parties[84] - The company has implemented a restricted stock incentive plan for 2023, with a 36-month lock-up period post-grant[84] - The company has made various commitments related to its IPO, including those from directors, supervisors, and senior management, which are long-term effective[84] - The company has established a long-term effective policy for handling other commitments, including those related to the IPO and equity incentives[84] - The company has made commitments related to the lock-up of shares held by its major shareholders and actual controller, with specific conditions for extending the lock-up period[88] - The company has established a long-term effective policy for handling other commitments, including those related to the IPO and equity incentives[88] - Shareholders holding more than 5% of the company's shares, including Da'an Gene, Guangzhou Da'an, Suzhou New Construction, and Tianfu Silicon Valley Zhenghui, have committed to a 12-month lock-up period post-listing, during which they will not transfer or entrust others to manage their shares[89] - Ningbo Daohe has also committed to a 12-month lock-up period post-listing, with similar restrictions on share transfers and management[90] - Directors, supervisors, and senior management indirectly holding shares through Ningbo Dingjie are subject to a 12-month lock-up period, with annual transfer limits of 25% of their holdings during their tenure[91] - Core technical personnel indirectly holding shares through Ningbo Dingjie are subject to a 12-month lock-up period, with annual transfer limits of 25% of their holdings for 4 years post-lock-up[92] - Actual controller Zhang Cheng has committed to adhering to IPO share lock-up and transfer restrictions, with specific rules for share reduction through various trading methods[93] - Controlling shareholder Hangzhou Yijia and related entities have committed to adhering to IPO share lock-up and transfer restrictions, with specific rules for share reduction through various trading methods[93] - The company's major shareholders, including Da'an Gene, Guangzhou Da'an, Suzhou New Yuan, and Silicon Valley Zhenghui, hold more than 5% of the company's shares and have committed to comply with IPO share lock-up and reduction rules[94] - If the company's stock price falls below the net asset value per share for 20 consecutive trading days within three years of listing, the company will initiate a stock price stabilization plan[95] - The company's controlling shareholder or its controlled entities will increase their shareholding by at least RMB 5 million within three months if the stock price stabilization plan is triggered, with the total number of shares not exceeding 2% of the company's total shares before the increase[96] - If the controlling shareholder fails to implement the share increase plan, the company may withhold cash dividends payable to the controlling shareholder until the cumulative amount reaches RMB 5 million[96] - If the stock price remains below the net asset value after the controlling shareholder's share increase, the company's directors (excluding independent directors) and senior management will increase their shareholding by at least 30% of their after-tax salary from the previous year within three months[96] - If the stock price remains below the net asset value after the directors' and senior management's share increase, the company will initiate a stock repurchase plan of at least RMB 10 million within three months, with the total number of shares not exceeding 2% of the company's total shares before the repurchase[96] - Any amendments to the stock price stabilization plan must be approved by at least two-thirds of the voting rights at the company's shareholders' meeting[96] - The company, its controlling shareholder, directors, and senior management must fulfill their obligations under the stock price stabilization plan in accordance with relevant regulations and disclose information accordingly[96] - The company's actual controller and related parties have extended the lock-up period for their pre-IPO shares by 6 months due to the stock price falling below the issue price for 20 consecutive trading days[100] - The company has committed to not providing loans or any form of financial assistance to incentive recipients for acquiring restricted shares under the incentive plan[99] - The company has outlined measures to prevent the dilution of immediate returns, including commitments from controlling shareholders, actual controllers, directors, and senior management[97] - The company's profit distribution policy prioritizes cash dividends and requires specific conditions to be met for cash dividends, such as positive undistributed profits and profitability[97] - The company has committed to avoiding conflicts of interest and ensuring that no illegal shareholding or improper benefits transfer occurs[98] Environmental and Social Responsibility - Environmental protection investment during the reporting period amounted to 3.46 million yuan[78] - Wastewater treatment includes industrial wastewater from metal part polishing and cleaning, and domestic sewage discharged into municipal sewage networks[78] - Waste gas from sterilization is treated using EO tail gas adsorption equipment before emission[78] - Solid waste from production is collected and processed by qualified units[78] - No carbon reduction measures or CO2 equivalent reductions were reported during the period[79] - No equity incentives, employee stock ownership plans, or other employee incentive measures were implemented or changed during the reporting period[77] - The company is not classified as a key pollutant discharge unit and has no significant pollution-related penalties[78] Legal and Regulatory Compliance - The company has disclosed that there are no significant lawsuits or arbitration cases during the

中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 部分募投项目延期的核查意见 | 项目名称 | 拟投入募集资金 | 累计投入金额 | 投资进度 | 原计划项目达到预 | | | | --- | --- | --- | --- | --- | --- | --- | | | 金额（元） | （元） | | 定可使用状态日期 | | | | 年产 1000 万件医用内 | | | | | | | | | 292,610,000.00 | 126,513,472.52 | 43.24% | 2024 年 8 31 | 月 | 日 | | 窥镜设备及器械项目 | | | | | | | 1 | 项目名称 | 拟投入募集资金 | 累计投入金额 | 投资进度 | 原计划项目达到预 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 金额（元） | （元） | | 定可使用状态日期 | | | | | 营销服务网络升级建 | 112,108,000.00 | 54,199,020.27 | 48.35% | 2025 年 月 | 12 | 31 ...

经中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕481 号）同意注册，并经上海证 券交易所同意，安杰思首次向社会公开发行人民币普通股（A 股）股票 1,447.0000 万股，发行价格为每股人民币 125.80 元，募集资金总额为人民币 182,032.60 万 元，扣除发行费用人民币（不含增值税）16,931.32 万元后，实际募集资金净额为 人民币 165,101.28 万元。上述募集资金已于 2023 年 5 月 16 日全部到位，并经天 健会计师事务所（特殊普通合伙）审验，于 2023 年 5 月 17 日出具了《验资报 告》（天健验〔2023〕210 号）。 安杰思按照规定对募集资金进行了专户管理，已与保荐人和专户存储募集资 金的商业银行签订了《募集资金专户存储三方监管协议》。 二、募集资金投资项目的基本情况 中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 使用部分超募资金永久补充流动资金的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股 ...

关于以集中竞价交易方式回购公司股份的进展公告 证券代码：688581 证券简称：安杰思 公告编号：2024-031 杭州安杰思医学科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/8，由董事长提议 | | --- | --- | | 回购方案实施期限 | 2024/2/7~2025/2/6 | | 预计回购金额 | 3,000 万元~5,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 40.14 万股 | | 累计已回购股数占总股本比 | 0.50% | | 例 | | | 累计已回购金额 | 万元 3,096.79 | | 实际回购价格区间 | 元/股~82.70 元/股 72.95 | 竞价交易方式回购公司股份方案的公告》（公告编号：2024-005）《安杰思关于以集 中竞价交易方式回购公司股份的回购报告书》（公告编 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [16]. Core Viewpoints - The company is recognized as a leading player in the domestic minimally invasive endoscopic medical device industry, with significant market visibility and growth potential [16]. - The domestic endoscopic medical device market is entering a development upgrade phase, with substantial room for domestic substitution of imported products [16]. - The company has a stable overseas customer base and is actively expanding its self-branded product sales [16]. - The company emphasizes differentiated innovation and has established an efficient R&D system, indicating strong future growth potential [16]. Summary by Sections Company Overview - The company, established in 2010, focuses on the design and development of minimally invasive interventional diagnostic and therapeutic products, achieving high market recognition in the endoscopic medical device sector [22][23]. Market Potential - The Chinese digestive endoscopic consumables market was valued at 3.73 billion yuan in 2019 and is projected to grow to 11.42 billion yuan by 2030, with a CAGR of 10.71% [16]. - The company’s market share for hemostatic clips reached 15.74% in 2022, with expectations for further growth as hospital coverage increases [16]. Financial Performance - The company forecasts net profits of 271 million yuan, 338 million yuan, and 423 million yuan for 2024, 2025, and 2026, respectively, with corresponding EPS of 3.35, 4.18, and 5.23 yuan [16][37]. - The company’s revenue is expected to grow from 636 million yuan in 2024 to 994 million yuan in 2026, maintaining a growth rate of 25% [37]. R&D and Innovation - The company maintains a stable R&D expense ratio of around 9%, focusing on product innovation and process optimization [16][30]. - Key technologies such as bipolar circuit technology and interchangeable technology are being commercialized, with multiple product lines under development [16][30]. Valuation Metrics - The current P/E ratios for 2024, 2025, and 2026 are projected at 15.2, 12.2, and 9.7, respectively, indicating a relatively low valuation compared to peers [16][37].